Buy Medivation (MDVN) Today, we recommend a biotech pick from Fidelity Select Biotechnology Portfolio (FBIOX), the best-performing health-sciences mutual fund over the last three years. Reflecting a consistent ability to pick winners, the FBIOX has ranked in the top 4 percent within its peer fund category in each of the last four years and its overall return over the last five-year period ranks at the very top-1 percent. One of the fund’s top holdings is Medivation (MDVN), an $8 billion. The company occupies a sweet spot in the biotech spectrum—unlike many of the smaller biotech companies, it already has Xtandi, a potential blockbuster, on the market but it’s also early enough in the drug’s life cycle that we think there’s significant upside remaining in the stock. Read More

Our stock indicators don’t like what they see from the market’s internals; they’ve turned negative this week and are anticipating at least a bit more selling in the short term. Should they point to even greater weakness we’ll look to capitalize, so remain vigilant for a possible Trade Alert. Meanwhile,… Read More

Despite its role as a safe haven, gold could find itself under a bit more pressure should the Greek crisis escalate, as the metal can be used as a source of liquidity. We would expect such pressure only in the early stage, however, and gold's current downside risk does not… Read More

Altogether, equities continue to look attractive, especially relative to fixed income securities, whose appreciation potential seems very limited in this environment. Also, this market environment should give us plenty of trading opportunities, as investors look at individual companies. The action in energy and materials stocks, which has been negative following… Read More